secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVS HEALTH Corp (CVS)
CIK:        0000064803
Form:       8-K
Filed at:   2024-10-18T23:59:59+00:00
Accession:  0001193125-24-239193
Event type: leadership
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

David Joyner named CVS Health CEO replacing Karen Lynch; preliminary Q3 EPS guide weak
--------------------------------------------------------------------------------

- David Joyner appointed President and CEO effective Oct. 17, 2024, succeeding Karen Lynch who resigned.
- Roger Farah elevated to Executive Chairman of the Board.
- Preliminary Q3 2024 GAAP diluted EPS $0.03-$0.08; adjusted EPS $1.05-$1.10.
- Results include $1.1B premium deficiency reserve charge and $1.2B restructuring charge.
- MBR expected ~95.2%; prior guidance withdrawn due to elevated medical cost trends.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/64803/000119312524239193/0001193125-24-239193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/64803/000119312524239193/d837701d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-239193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer